

8<sup>th</sup> September 2016

## **Optiscan Completes \$2.16M Capital Raising**

### **Optiscan well funded to drive Strategic Direction and Deliver Shareholder Wealth**

Optiscan is delighted to announce that it has completed the final stages of its \$2.16M Capital Raising as follows:

- \$0.75M from sophisticated and professional investors;
- \$0.55M from the Rights Issue take-up from existing shareholders; and
- \$0.86M from Underwriters/Sub-Underwriters of the Rights Issue.

Optiscan is now well funded to continue to drive the strategic direction of the company:

- Driving the commercialisation of the CellLIVE product;
- Development and commercialisation of a flexible probe;
- Development and commercialisation of the 2nd generation rigid system; and
- Completion and launch of the Carl Zeiss collaboration project.

The Rights Issue is the latest building block in the restructure and redevelopment of Optiscan that has included the new board (announced on 3 May 2016) and the appointment of Archie Fraser as CEO (announced on 13 May 2016) all of which will combine to deliver on the company's new mission:

*"To create shareholder wealth through the profitable delivery of microscopic imaging and related technologies into the global market."*

We wish to sincerely thank all our shareholders, investors and underwriters for their contribution to the future of Optiscan and for their confidence in our future direction.

We look forward to delivering on the Optiscan mission for the benefit of our shareholders, stakeholders and strategic partners.

Kind regards,



Alan Hoffman  
Chairman

## **About Optiscan**

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical markets.

Further information:

Alan Hoffman  
Chairman  
Mb: +61 408 968 013  
Em: [alanh@optiscan.com](mailto:alanh@optiscan.com)

Archie Fraser  
CEO  
Ph: +61 3 9538 3333  
Em: [archiefraser@optiscan.com](mailto:archiefraser@optiscan.com)